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clinically acceptable, however the H&N FFF plans have lower 
pass rates. This can be related to the MLC modulation needed 
to compensate for the inhomogeneous beam profile using FFF 
for larger targets. Same trend is seen for the lung 
treatments, where there is a range of target sizes. 
 
 
Conclusions: Clinically acceptable FFF treatment plans can 
be created and delivered for normally fractionated 
treatments in all three anatomical sites. The reduced head 
scatter from removing the flattening filter produces reduced 
total body dose, which could be clinically relevant to the aim 
of reducing secondary cancers. 
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Purpose/Objective: Evaluation of the characteristics of the 
new EPID PV-aS1200 by Varian for its dosimetric usage with 
the GLAaS algorithm, where a dedicate configuration phase 
allows to convert the EPID reading into absorbed dose to 
water. 
Materials and Methods: The new PV-aS1200 imager has an 
active area of a 40x40cm2 (1190x1190 pixel), with a 
backscatter shielding included in the new cassette 
engineering. Its intrinsic characteristics were investigated on 
an Edge accelerator equipped with 6X, 6FFF, 10FFF beams. 
For the same energies, data were also compared to PV-
aS1000 acquisitions from a TrueBeam.  
A first level of investigations covered signal linearity with 
dose, response to primary and transmitted radiation, 
saturation relative to dose and dose rate, arm backscatter as 
a function of field size, ghosting. After that first detector 
assessment, the robustness of the GLAaS dose calibration 
process was evaluated in terms of absolute absorbed dose, 
relative output factors and profile parameters. 
Finally, GLAaS was validated for aS1200 as pre-treatment QA 
tool for RapidArc plans, covering different dose/fraction 
prescriptions. The mutual position of the detector and the 
linac head was measured in a cine mode during full rotations. 
Results: For all energies, aS1200 readings showed an optimal 
linearity relative to MU (R2=1.00), with a residual deviation 
less than 0.5% for more than 3MU. The detector response to 
primary and transmitted radiation was modelled and showed 
to be similar to the aS100 detector. The aS1200 confirmed to 
have no saturation for measurements at isocenter and the 
maximum dose rate (1400 and 2400 MU/min for 6 and 10FFF 
respectively). The arm backscatter variation with field size is 
now compensated with the new engineering. Consequently 
the dose calibration according to the GLAaS model was 
successfully implemented, allowing QA for all beams with no 
limitations of field size or dose rate.  
Comparison between measured dose map and TPS calculated 
dose in water was assessed through the Gamma Agreement 
Index GAI, for different DTA and ΔD criteria, resulting in GAI 
> 95% (2%, 2mm criteria).  
Conclusions: The new aS1200 detector improved the 
performance of the previous aS1000, with no more limitation 
in terms of field size and/or dose rate. The effective 
resolution of arm backscatter allows a more robust usage of 
the new detector. The usability for pre-treatment QA for 
RapidArc cases is confirmed in all conditions, from 
stereotactic to very large volumes, from common to very high 
dose rates. 
 
 
Poster: Physics track: Treatment planning calculation, 
optimisation  
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Purpose/Objective: By creating Pareto fronts for Helical 
TomoTherapy (HT) plans, the influence of field width (FW), 
modulation factor (MF) and pitch on the plan quality can be 
investigated and Pareto optimal combinations can be 
deduced. 
Materials and Methods: For every oropharyngeal cancer 
patient out of five, 90 TomoEdge plans were made (each with 
a unique combination of MF and pitch) [1-2]. The 
homogeneity index (HI), conformity index (CI), Dnear-max (D2) 
and Dnear-min (D98) of the PTVs were plotted in a Pareto front 
